Drugmaker Novartis announced 10 members to its newly formed Sandoz board of directors May 15 ahead of its previously announced biosimilar spinoff. The Sandoz spinoff is an effort the company is making to keep a competitive pace with rising costs of brand name drugs.
Read the full post on Becker's Hospital Review - Healthcare News
